Abstract
Hemorrhagic cystitis (HC) secondary to BK polyomavirus (BKPyV) is a frequent complication related to allogenic stem cell transplantation. With an important morbidity and mortality, this disease doesn’t have a stablished standard treatment or prophylaxis strategies. At this moment, the supportive therapies approved to treat included hyperhydration, forced diuresis and transfusion support. Cidofovir is a nucleotide analog of deoxycytidine monophosphate against DNA viruses and it has been described for the treatment of BKPyV-HC, but at this moment, is not a front-line therapy. We report a successful case after the use of Cidofovir without Probenecid. No adverse effect was developed under the treatment, and after 4 weeks of treatment, the patient achieved an excellent response.
Highlights
BK polyomavirus (BKPyV) is a challengo ing complication in patients with hematoN logic disease undergoing hematopoietic bone marrow aspirate for reevaluation showed positive metabolic residual disease (0.53%) by immunophenotype, and positive mutated NPM1 with 14.7 copies, diagnosing a relapse of his leukemia
At day 82 post-transplant, he went to the emergency room with tenesmus and dysuria without fever and macroscopic hematuria
Antibiotic treatment was started without improvement and worsening with the presence of macroscopic hematuria
Summary
Hemorrhagic cystitis (HC) secondary to BK polyomavirus (BKPyV) is a frequent complication related to allogenic stem cell ly transplantation. It was decided to perform an allogeneic bone marrow transplantation of identical HLA sister, and he received prophylaxis to graft versus host disease (GVHD) with cyclosporine and short-term methotrexate. He evolved favorably until day 60 post-transplant, when he showed a cutaneous GVHD that it was resolved with corticosteroids and cyclosporine. Stem cell transplant (HSCT), with a variable Urology service ruling out structural patholprevalence depending of several factors ogy of the genitourinary system The such as age, sex and previous treatments.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
